FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328130580> ?p ?o ?g. }

• W4328130580 abstract "Abstract Background Metastatic breast cancer (MBC) is a challenging disease, and despite new therapies, prognosis is still poor for a majority of patients. There is a clinical need for improved prognostication where immuno-oncology markers can provide important information. The aim of this study was to evaluate serum immuno-oncology markers in MBC patients and their respective relevance for prediction of survival. Patients and methods We investigated a broad panel of 92 immuno-oncology proteins in serum from 136 MBC patients included in a prospective observational study (NCT01322893) with long-term follow-up. Serum samples were collected before start of systemic therapy and analyzed using multiplex proximity extension assay (Olink Target 96 Immuno-Oncology panel). Multiple machine learning techniques were used to identify serum markers with highest importance for prediction of overall and progression-free survival (OS and PFS), and associations to survival were further evaluated using Cox regression analyses. False discovery rate was then used to adjust for multiple comparisons. Results Using random forest and random survival forest analyses, we identified the top nine and ten variables of highest predictive importance for OS and PFS, respectively. Cox regression analyses revealed significant associations ( P < 0.005) of higher serum levels of IL-8, IL-10 and CAIX with worse OS in multivariable analyses, adjusted for established clinical prognostic factors including circulating tumor cells (CTCs). Similarly, high serum levels of IL-8, IL-10, ADA and CASP8 significantly associated with worse PFS. Interestingly, high serum levels of FasL significantly associated with improved OS and PFS. In addition, CSF-1, IL-6, MUC16, TFNSFR4 and CD244 showed suggestive evidence ( P < 0.05) for an association to survival in multivariable analyses. After correction for multiple comparisons, IL-8 still showed strong evidence for correlation to survival. Conclusion To conclude, we found six serum immuno-oncology markers that were significantly associated with OS and/or PFS in MBC patients, independently of other established prognostic factors including CTCs. Furthermore, an additional five serum immuno-oncology markers provided suggestive evidence for an independent association to survival. These findings highlight the relevance of immuno-oncology serum markers in MBC patients and support their usefulness for improved prognostication. Trial registration Clinical Trials (NCT01322893), registered March 25, 2011." @default.
• W4328130580 created "2023-03-22" @default.
• W4328130580 creator A5010340306 @default.
• W4328130580 creator A5015244514 @default.
• W4328130580 creator A5035421457 @default.
• W4328130580 creator A5039489405 @default.
• W4328130580 creator A5061921179 @default.
• W4328130580 creator A5081536466 @default.
• W4328130580 creator A5087257302 @default.
• W4328130580 date "2023-03-21" @default.
• W4328130580 modified "2023-10-10" @default.
• W4328130580 title "Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study" @default.
• W4328130580 cites W1543776368 @default.
• W4328130580 cites W185803695 @default.
• W4328130580 cites W1966230941 @default.
• W4328130580 cites W1999381573 @default.
• W4328130580 cites W2010084870 @default.
• W4328130580 cites W2014643064 @default.
• W4328130580 cites W2078529338 @default.
• W4328130580 cites W2079989335 @default.
• W4328130580 cites W2102260696 @default.
• W4328130580 cites W2107444404 @default.
• W4328130580 cites W2110065044 @default.
• W4328130580 cites W2114129118 @default.
• W4328130580 cites W2117679109 @default.
• W4328130580 cites W2118075066 @default.
• W4328130580 cites W2122944628 @default.
• W4328130580 cites W2123583989 @default.
• W4328130580 cites W2130672532 @default.
• W4328130580 cites W2140878328 @default.
• W4328130580 cites W2153333117 @default.
• W4328130580 cites W2156323704 @default.
• W4328130580 cites W2160046825 @default.
• W4328130580 cites W2508023113 @default.
• W4328130580 cites W2540177567 @default.
• W4328130580 cites W2560635244 @default.
• W4328130580 cites W2608202513 @default.
• W4328130580 cites W2610505842 @default.
• W4328130580 cites W2612557208 @default.
• W4328130580 cites W2736848882 @default.
• W4328130580 cites W2775740235 @default.
• W4328130580 cites W2802505506 @default.
• W4328130580 cites W2806005235 @default.
• W4328130580 cites W2900626521 @default.
• W4328130580 cites W2902074696 @default.
• W4328130580 cites W2912010952 @default.
• W4328130580 cites W2934855318 @default.
• W4328130580 cites W3007935666 @default.
• W4328130580 cites W3011979269 @default.
• W4328130580 cites W3013443751 @default.
• W4328130580 cites W3039577880 @default.
• W4328130580 cites W3039724956 @default.
• W4328130580 cites W3081303340 @default.
• W4328130580 cites W3136157395 @default.
• W4328130580 cites W3139363597 @default.
• W4328130580 cites W3141477374 @default.
• W4328130580 cites W3144121525 @default.
• W4328130580 cites W3194945739 @default.
• W4328130580 cites W3208195983 @default.
• W4328130580 cites W4200380682 @default.
• W4328130580 cites W4205527782 @default.
• W4328130580 cites W4206666777 @default.
• W4328130580 cites W4285743699 @default.
• W4328130580 doi "https://doi.org/10.1186/s13058-023-01631-6" @default.
• W4328130580 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36945037" @default.
• W4328130580 hasPublicationYear "2023" @default.
• W4328130580 type Work @default.
• W4328130580 citedByCount "0" @default.
• W4328130580 crossrefType "journal-article" @default.
• W4328130580 hasAuthorship W4328130580A5010340306 @default.
• W4328130580 hasAuthorship W4328130580A5015244514 @default.
• W4328130580 hasAuthorship W4328130580A5035421457 @default.
• W4328130580 hasAuthorship W4328130580A5039489405 @default.
• W4328130580 hasAuthorship W4328130580A5061921179 @default.
• W4328130580 hasAuthorship W4328130580A5081536466 @default.
• W4328130580 hasAuthorship W4328130580A5087257302 @default.
• W4328130580 hasBestOaLocation W43281305801 @default.
• W4328130580 hasConcept C121608353 @default.
• W4328130580 hasConcept C126322002 @default.
• W4328130580 hasConcept C143998085 @default.
• W4328130580 hasConcept C188816634 @default.
• W4328130580 hasConcept C23131810 @default.
• W4328130580 hasConcept C2775930923 @default.
• W4328130580 hasConcept C2780140570 @default.
• W4328130580 hasConcept C50382708 @default.
• W4328130580 hasConcept C530470458 @default.
• W4328130580 hasConcept C71924100 @default.
• W4328130580 hasConceptScore W4328130580C121608353 @default.
• W4328130580 hasConceptScore W4328130580C126322002 @default.
• W4328130580 hasConceptScore W4328130580C143998085 @default.
• W4328130580 hasConceptScore W4328130580C188816634 @default.
• W4328130580 hasConceptScore W4328130580C23131810 @default.
• W4328130580 hasConceptScore W4328130580C2775930923 @default.
• W4328130580 hasConceptScore W4328130580C2780140570 @default.
• W4328130580 hasConceptScore W4328130580C50382708 @default.
• W4328130580 hasConceptScore W4328130580C530470458 @default.
• W4328130580 hasConceptScore W4328130580C71924100 @default.
• W4328130580 hasFunder F4320316590 @default.
• W4328130580 hasFunder F4320321806 @default.
• W4328130580 hasFunder F4320321929 @default.

• next